BARCELONA, Spain, June 28, 2017 / / -- Results from Halozyme Therapeutics (NASDAQ: HALO) Phase 2 randomized, multi-center clinical trial in pancreas cancer patients were shared today in two oral presentations at the European Society for Medical Oncology's 19th World Congress on Gastrointestinal Cancer.
↧